Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

25.98 +2.18 (+9.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,407,514
Open 24.28
Bid (Size) 25.80 (1)
Ask (Size) 25.96 (46)
Prev. Close 23.80
Today's Range 24.19 - 26.45
52wk Range 11.76 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday. 
Via Stocktwits
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
From Summit Therapeutics
Via Business Wire

Performance

YTD
+41.6%
+41.6%
1 Month
-8.9%
-8.9%
3 Month
+26.2%
+26.2%
6 Month
+46.1%
+46.1%
1 Year
+107.8%
+107.8%

More News

Read More
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio?
Via Benzinga
3 No-Brainer Stocks to Buy Right Now
Via The Motley Fool
Topics World Trade
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Via Benzinga
JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside
Via Stocktwits
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
From Summit Therapeutics
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
From Summit Therapeutics
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Via The Motley Fool
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Why Is AbbVie Stock Trading Higher On Thursday?
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Via Benzinga
Topics Intellectual Property

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 25.98
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 09/05/25 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 2.53B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.